psychedelic drugs

The psychedelic drug development landscape has reached an inflection point in early 2026, with Compass Pathways achieving the first positive Phase 3 psilocybin trial results in June 2025, while Lykos Therapeutics' MDMA rejection has reshaped industry expectations for regulatory rigor. Six...

"It seems that psychedelics do more than simply alter perception. According to the latest research from my colleagues and me, they change the structures of neurons themselves. My research group has been studying the effects of psychedelics on neuronal structure and function, and we found that...